Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy

Schizophrenia Research

Volumn 148, Issue 1-3, 2013, Pages 138-144

  Deutsch, Stephen I ^a,b   Schwartz, Barbara L ^b,c   Schooler, Nina R ^b,c   Brown, Clayton H ^d   Rosse, Richard B ^b,c   Rosse, Stephanie M ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Alpha7 nicotinic receptor; Negative symptoms; Neurocognition; Positive allosteric modulator; Schizophrenia

Indexed keywords

BUNGAROTOXIN RECEPTOR; CITICOLINE; GALANTAMINE; NEUROLEPTIC AGENT; PLACEBO;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; COGNITION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE TITRATION; DRUG TARGETING; DRUG WITHDRAWAL; FAINTNESS; FEMALE; FEVER; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERSALIVATION; INDIGESTION; INSOMNIA; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NEGATIVE SYNDROME; NEUROTRANSMISSION; NOSE OBSTRUCTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; RESTLESSNESS; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SWEATING; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ACETYLCHOLINE; ALPHA7 NICOTINIC RECEPTOR; NEGATIVE SYMPTOMS; NEUROCOGNITION; POSITIVE ALLOSTERIC MODULATOR; SCHIZOPHRENIA;

ADULT; AGED; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; COGNITION DISORDERS; CYTIDINE DIPHOSPHATE CHOLINE; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 84881027906     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.05.023     Document Type: Article

References (43)

1. Albuquerque E.X., Alkondon M., Pereira E.F.R., Castro N.G., Schrattenholz A., Barbosa C.T.F., Bonfante-Cabarcas R., Aracava Y., Eisenberg H.M., Maelicke A. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J. Pharmacol. Exp. Ther. 1997, 280(3):1117-1136.
2. Albuquerque E.X., Pereira E.F.R., Braga M.F.M., Alkondon M. Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of α7 receptors. J. Physiol. Paris 1998, 92:309-316.
3. 7 nicotinic acetylcholine receptors in the rat brain neurons. Eur. J. Neurosci. 1997, 9:2734-2742.
4. Blair J.R., Spreen O. Predicting premorbid IQ: a revision of the National Adult Reading Test. Clin. Neuropsychol. 1989, 3:129-136.
5. Clark W.M., Warach S.J., Pettigrew L.C., Group Stroke Study, et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology 1997, 49:671-678.
6. Clark W.M., Williams B.J., Selzer K.A., Zweifler R.M., Sabounjian L.A., Gammans R.E. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999, 30:2592-2597.
7. Conley R.R., Boggs D.L., Kelly D.L., McMahon R.P., Dickinson D., Feldman S., Ball M.P., Buchanan R.W. The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin. Neuropharmacol. 2009, 32(2):69-74.
8. Court J., Spurden D., Lloyd S., McKeith I., Ballard C., Cairns N., Kerwin R., Perry R., Perry E. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: α-bingarotoxin and nicotine binding in thalamus. J. Neurochem. 1999, 73:1590-1597.
9. Dani J.A., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 2007, 47:699-729.
10. Davalos A., Castillo J., Alvarez-Sabin J., Secades J.J., Mercadal J., López S., Cobo E., Warach S., Shermanm D., Clark W.M., Lozano R. Oral citicoline in acute ischemic stroke. An individual patient data pooling analysis of clinical trials. Stroke 2002, 33:2850-2857.
11. Deutsch S.I., Rosse R.B., Schwartz B.L., Weizman A., Chilton M., Arnold D.S., Mastropaolo J. Therapeutic implications of a selective α7 nicotinic receptor abnormality in schizophrenia. Isr. J. Psychiatry Relat. Sci. 2005, 42(1):33-44.
12. Deutsch S.I., Schwartz B.L., Schooler N.R., Rosse R.B., Mastropaolo J., Gaskins B. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy. Clin. Neuropharmacol. 2008, 31(1):34-39.
13. Feingold A. Effect sizes for growth-modeling analysis for controlled clinical trials in the same metric as for classical analysis. Psychol. Methods 2009, 14(1):43-53.
14. Fioravanti M., Yanagi M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst. Rev. 2004, 4:CD000269.
15. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1996, American Psychiatric Press, Inc., Washington (DC).
16. Fitzmaurice G.M., Laird N.M., Ware J.H. Applied Longitudinal Analysis 2011, 128-134. John Wiley, Hoboken. 2nd ed.
17. Freedman R., Hall M., Adler L.E., Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry 1995, 38:22-33.
18. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:587-592.
19. Freedman R., Olincy A., Buchanan R.W., Harris J.G., Gold J.M., Johnson L., Allensworth D., Gusman-Bonilla A., Clement B., Ball M.P., Kutnick J., Pender V., Martin L.F., Stevens K.E., Wagner B.D., Zerbe G.O., Soti F., Kem W.R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 2008, 165:1040-1047.
20. Geyer M.A., Tamminga C.A. Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects. Psychopharmacology 2004, 174:1-2.
21. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26(1):119-136.
22. Gregory K.J., Dong E.N., Meiler J., Conn P.J. Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 2011, 60(1):66-81.
23. Guan Z.Z., Zhang X., Blennow K., Nordberg A. Decreased protein level of nicotinic receptor [alpha]7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 1999, 10(8):1779-1782.
24. Heckers S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 2001, 11:520-528.
25. Heckers S., Rauch S., Goff D., Savage C., Schacter D., Fischman A., Alpert N.M. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat. Neurosci. 1998, 1:318-323.
26. Ji D., Lape R., Dani J.A. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 2001, 231:131-141.
27. Jones C.K., Byun N., Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacol. Rev. 2011, 1-27.
28. Kay S.R., Opler L.A., Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br. J. Psychiatry 1989, 155(Suppl 7):59-65.
29. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., Drebing C., Berger R., Venn D., Sirota P., Zerbe G., Olincy A., Ross R.G., Adler L.E., Freedman R. Promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene are associated with an inhibitory deficit found in schizophrenia. Arch. Gen. Psychiatry 2002, 59:1085-1090.
30. Lieberman J.A., Dunbar G., Segreti A.C., Girgis R.R., Seonane F., Beaver J.S., Duan N., Hosford D.A. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 2013, 8:968-975.
31. Lightfoot A.P., Kew J.N.C., Skidmore J. α7 nicotinic acetylcholine receptor agonists and positive allosteric modulators. Prog. Med. Chem. 2008, 46:131-171.
32. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58(12):538-546.
33. Martin L.F., Freedman R. Schizophrenia and the α7 nicotinic acetylcholine receptor. Int. Rev. Neurobiol. 2007, 78:225-246.
34. National Institute of Mental Health CGI: Clinical Global Impressions. Manual for the ECDEU Assessment Battery 1970, Chevy Chase. 2nd ed. W. Guy, R.R. Bonato (Eds.).
35. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., Essock S., Fenton W.S., Frese F.J., Gold J.M., Goldberg T., Heaton R.K., Keefe R.S.E., Kraemer H., Mesholam-Gately R., Seiman L.J., Stover E., Weinberger D.R., Young A.S., Zalcman S., Marder S.R. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 2008, 165(2):203-213.
36. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., Ellis J., Zerbe G.O., Leonard S., Stevens K.E., Stevens J.O., Martin L., Adler L.E., Soti F., Kem W.R., Freedman R. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 2006, 63:630-638.
37. Parker E.S., Landau S.M., Whipple S.C., Schwartz B.L. Aging, recall, and recognition: a study on the sensitivity of the University of Southern California Repeatable Episodic Memory Test (USC-REMT). J. Clin. Exp. Neuropsychol. 2004, 26(3):428-440.
38. Ragland J.D., Laird A.R., Ranganath C., Blumenfeld R.S., Gonzales S.M., Glahn D.C. Prefrontal activation deficits during episodic memory in schizophrenia. Am. J. Psychiatry 2009, 166(8):863-874.
39. Rapaport M.H., Bazzetta J., McAdams L.A., Patterson T., Jeste D.V. Validation of the scale of functioning in older outpatients with schizophrenia. Am. J. Geriatr. Psychiatry 1996, 4(3):218-228.
40. Rousseau S.J., Jones I.W., Pullar I.A., Wonnacott S. Presynaptic α7 and non-α7 nicotinic acetylcholine receptors modulate [3H]d-aspartate release from rat frontal cortex in vitro. Neuropharmacology 2005, 49:59-72.
41. Schwartz B.L., Parker E.S., Rosse R.B., Deutsch S.I. Recognition memory probes affect what is remembered in schizophrenia. Psychiatry Res. 2009, 167:21-27.
42. Wurtman R.J., Regan M., Ulus I., Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem. Pharmacol. 2000, 60(7):989-992.
43. Wurtman R.J., Schwamm L.H., Kelly P.J., et al. Citicoline: Efficacy & Safety Review: Clinical Expert Report. Submission to the Regulatory Authorities of Belgium and Portugal for the European Economic Community 2001, Ferrer Internacional, S.A., Barcelona, España.